Percutaneous coronary intervention in chronic stable angina. 2010

Konstantinos Toutouzas, and Andreas Synetos, and Antonis Karanasos, and Maria Drakopoulou, and Eleutherios Tsiamis, and Stamatios Lerakis, and Christodoulos Stefanadis
First Department of Cardiology, Hippokration Hospital, University of Athens, Greece.

Although the therapeutic advantage of percutaneous coronary intervention in acute coronary syndromes have been proved in numerous studies, its position in the treatment of stable angina remains a controversial issue. The results of the recent studies did not lead into definite answers for the proper treatment of chronic coronary artery disease. The identification of the patients that will benefit from the interventional approach is necessary and is probably based on the proper screening for myocardial ischemia with noninvasive diagnostic techniques. In this review article, we mention the most recent studies for the treatment of chronic stable angina with respect to clinical outcome and economical consequences.

UI MeSH Term Description Entries
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000787 Angina Pectoris The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION. Angor Pectoris,Stenocardia,Stenocardias
D015906 Angioplasty, Balloon, Coronary Dilation of an occluded coronary artery (or arteries) by means of a balloon catheter to restore myocardial blood supply. Angioplasty, Coronary Balloon,Angioplasty, Transluminal, Percutaneous Coronary,Coronary Angioplasty, Transluminal Balloon,Percutaneous Transluminal Coronary Angioplasty,Balloon Dilation, Coronary Artery,Transluminal Coronary Balloon Dilation,Angioplasties, Coronary Balloon,Balloon Angioplasties, Coronary,Balloon Angioplasty, Coronary,Coronary Balloon Angioplasties,Coronary Balloon Angioplasty
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D018570 Risk Assessment The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988) Assessment, Risk,Benefit-Risk Assessment,Risk Analysis,Risk-Benefit Assessment,Health Risk Assessment,Risks and Benefits,Analysis, Risk,Assessment, Benefit-Risk,Assessment, Health Risk,Assessment, Risk-Benefit,Benefit Risk Assessment,Benefit-Risk Assessments,Benefits and Risks,Health Risk Assessments,Risk Analyses,Risk Assessment, Health,Risk Assessments,Risk Benefit Assessment,Risk-Benefit Assessments

Related Publications

Konstantinos Toutouzas, and Andreas Synetos, and Antonis Karanasos, and Maria Drakopoulou, and Eleutherios Tsiamis, and Stamatios Lerakis, and Christodoulos Stefanadis
January 2011, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese,
Konstantinos Toutouzas, and Andreas Synetos, and Antonis Karanasos, and Maria Drakopoulou, and Eleutherios Tsiamis, and Stamatios Lerakis, and Christodoulos Stefanadis
February 2018, The American journal of nursing,
Konstantinos Toutouzas, and Andreas Synetos, and Antonis Karanasos, and Maria Drakopoulou, and Eleutherios Tsiamis, and Stamatios Lerakis, and Christodoulos Stefanadis
February 2008, JACC. Cardiovascular interventions,
Konstantinos Toutouzas, and Andreas Synetos, and Antonis Karanasos, and Maria Drakopoulou, and Eleutherios Tsiamis, and Stamatios Lerakis, and Christodoulos Stefanadis
August 2010, Evidence-based medicine,
Konstantinos Toutouzas, and Andreas Synetos, and Antonis Karanasos, and Maria Drakopoulou, and Eleutherios Tsiamis, and Stamatios Lerakis, and Christodoulos Stefanadis
July 2018, Lancet (London, England),
Konstantinos Toutouzas, and Andreas Synetos, and Antonis Karanasos, and Maria Drakopoulou, and Eleutherios Tsiamis, and Stamatios Lerakis, and Christodoulos Stefanadis
July 2018, Lancet (London, England),
Konstantinos Toutouzas, and Andreas Synetos, and Antonis Karanasos, and Maria Drakopoulou, and Eleutherios Tsiamis, and Stamatios Lerakis, and Christodoulos Stefanadis
July 2018, Lancet (London, England),
Konstantinos Toutouzas, and Andreas Synetos, and Antonis Karanasos, and Maria Drakopoulou, and Eleutherios Tsiamis, and Stamatios Lerakis, and Christodoulos Stefanadis
July 2018, Lancet (London, England),
Konstantinos Toutouzas, and Andreas Synetos, and Antonis Karanasos, and Maria Drakopoulou, and Eleutherios Tsiamis, and Stamatios Lerakis, and Christodoulos Stefanadis
July 2018, Lancet (London, England),
Konstantinos Toutouzas, and Andreas Synetos, and Antonis Karanasos, and Maria Drakopoulou, and Eleutherios Tsiamis, and Stamatios Lerakis, and Christodoulos Stefanadis
July 2018, Lancet (London, England),
Copied contents to your clipboard!